Abstract：Objective To observe the clinical effect of Compound Saponin Pills in the treatment of multidrug-resistant tuberculosis. Methods Forty patients with multidrug-resistant tuberculosis admitted to our hospital from June 2016 to December 2018 were selected as subjects. According to the random number table method, they were divided into experimental group and control group, 20 cases in each group. The two groups were used 3 to 5 sensitive anti-tuberculosis drugs according to the previous medication history and drug susceptibility test results. Conventional basic chemotherapy, the experimental group was added with Compound Saponin Pills orally on the original basis. The sputum negative conversion, chest X-ray lesion absorption, cavity closure rate and T cell subsets were observed after treatment in the two groups. Results There was no significant difference in the rate of sputum negative conversion between the two groups after 1, 2, 3, 4, 5, 6 months of treatment (P＞0.05), there was no significant difference in the total effective rate between the two groups after 6 months of treatment (P＞0.05), but serum CD4+, CD4+/CD8+ in the experimental group after treatment for 3 months and the cavity closure rate after treatment for 6 months were higher than those of the control group, and the CD8+ was lower than that of the control group. The differences were statistically significant (P＜0.05). Conclusion Compound Saponin Pills for the treatment of multidrug-resistant tuberculosis can increase the lung cavity absorption rate, significantly improve the cellular immune function and improve the prognosis of patients.
程吕欢；邓建仟；李娅娜；舒维. 复方皂矾丸辅助治疗耐多药肺结核的临床效果[J]. 中国当代医药, 2020, 27(6): 36-39.
CHENG Lyu-huan1 DENG Jian-qian2 LI Ya-na3 SHU-Wei2. Clinical effect of Compound Saponin Pills in the treatment of multidrugresistant pulmonary tuberculosis. 中国当代医药, 2020, 27(6): 36-39.
Edlin BR，Tokars JI，Grieco MH，et al.An outbreak of multidrugresistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome[J].N Engl J Med，1992，326（23）：1514-1521.
Liu Z，Dong H，Wu B，et al.Is rifampin resistance a reliable predictive marker of multidrug -resistant tuberculosis in China：A meta-analysis of findings[J].J Infect，2019，79（4）：349-356.
[8]
CohnDL，BustreoF，RaviglioneMC.Drug-resistanttuberculosis：review of the worldwide situation and the WHO/IUATLD Global Surveillance Project.International Union Against Tuberculosis and Lung Disease[J].Clin Infect Dis，1997，24（Suppl 1）：S121-S130.
[9]
Sharma P，Lalwani J，Pandey P，et al.Factors associated with the development of secondary multidrug-resistant tuberculosis[J].Int J Prev Med，2019，10：67.
[10]
Aznar ML，Segura AR，Moreno MM，et al.Treatment outcomes and adverse events from a standardized multidrug-resistant tuberculosis regimen in a rural setting in angola[J].Am J Trop Med Hyg，2019，101（3）：502-509.
京公网安备 11010502046607号